OrthoPediatrics expands bracing division with new clinics in US and Ireland

WARSAW, Ind. - OrthoPediatrics Corp. (NASDAQ:KIDS), a pediatric orthopedics company with a market capitalization of approximately $499 million, announced Tuesday the expansion of its Specialty Bracing division with multiple new clinics across the United States and its first international location in Ireland. The expansion comes as the company’s stock trades near its 52-week low, having declined about 30% over the past year, according to InvestingPro data.

The pediatric orthopedics company has opened new clinics in California, Ohio, and Colorado as part of its greenfield expansion strategy. The Los Angeles clinic marks the division’s first entry into the California market, providing access to millions of potential pediatric and adolescent patients. This expansion aligns with the company’s strong revenue growth of 31% in the last twelve months, as reported by InvestingPro.

In Ohio, the company established a new clinic in Dayton Children’s Hospital, while in Colorado, multiple clinics with experienced clinicians were added to cover the Denver territory.

OrthoPediatrics also expanded through what it terms "Acquihire opportunities" in New York and Ireland. The New York operation added multiple patient locations to its existing two clinics, all situated within major children’s hospital centers.

The Ireland location represents the company’s first international market for its bracing division, complementing OrthoPediatrics’ existing implant business presence in one of the country’s largest pediatric hospitals.

"We are thrilled to announce this continued expansion as we are slightly ahead of our planned entry into 4 new target markets in 2025," said Joe Hauser, President of the OrthoPediatrics Specialty Bracing division, in the press release.

Michael C. Albert, Division Chief of Pediatric Orthopedics at Dayton Children’s Hospital, stated, "Partnering with OPSB to bring O&P care on-site will greatly benefit all our patients and our community."

OrthoPediatrics, founded in 2006, focuses exclusively on pediatric orthopedics and currently markets over 80 products across trauma and deformity, scoliosis, and sports medicine categories in the United States and more than 70 countries worldwide. The company maintains a healthy gross profit margin of 73% and strong liquidity with a current ratio of 6.19. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks including OrthoPediatrics.

In other recent news, OrthoPediatrics Corp. has made several noteworthy announcements. The company reported the results of its 2025 Annual Meeting of Stockholders, where directors were elected to serve until the 2028 Annual Meeting. In a strategic move, OrthoPediatrics amended the terms of its acquisition agreement with Medtech Concepts, LLC. The amendment changes the payment method to the sellers from cash to unregistered shares of OrthoPediatrics common stock, valued at approximately $3,750,000, distributed over three years.

Meanwhile, Stifel analysts have reiterated their Buy rating on OrthoPediatrics, maintaining a $32.00 price target, following their attendance at the Pediatric Orthopaedic Society of North America Meeting. BTIG analysts also maintained a Buy rating, with a $38.00 price target, after engaging with pediatric orthopedists at the same meeting. Feedback from the event suggests a robust procedural volume for the upcoming Summer season, with schedules booked through the Fall. These developments reflect ongoing confidence in OrthoPediatrics’ market position and growth potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.